Interview: GSK India's Playbook For Vaccines Dominance
Deft pricing and effective physician engagement appear to have helped shape GSK's sustained dominance in the Indian self-pay vaccines market. GSK Pharmaceuticals India managing director, Annaswamy Vaidheesh, takes Scrip through some of the strategies at play including the sharp recalibration in the price of Synflorix and how the British multinational is harnessing digital technology to stay "close" to its customers.
You may also be interested in...
Bharat hopes to expand international reach of Chiron Behring’s rabies vaccine. WuXi and Biolingus partner on sublingual delivery.
Ruling could come as early as next month in international humanitarian group MSF’s challenge to Pfizer's application for Indian patent on its blockbuster pneumococcal vaccine; observers see ruling as test of whether India is sticking to its stringent patent policy in face of growing pressure from foreign pharmaceutical companies.
Competition in the fast growing Indian respiratory products market looks set to intensify with key players and traditional rivals, Cipla and GlaxoSmithKline, each outlining distinct new initiatives in the segment.